Trial Profile

A phase Ib/II clinical evaluation of Ponatinib in combination with 5- Azacitidine in patients failing prior therapy for FLT3-ITD positive acute myeloid leukaemia (AMLM21)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 18 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Dec 2021 Results (n=31) presented at the 63rd American Society of Hematology Annual Meeting and Exposition
20 Sep 2021 Phase of the trial is changed from 1/2 to 1. Phase II portion of trial has been removed from the study after enrolment of 20 participants. The removal of the Azacitidine alone arm was done during protocol development, as this was considered an unnecessary control. There are now only 2 arms; Ponatinib alone vs Ponatinib/Azacitidine.
20 Sep 2021 Planned number of patients changed from 60 to 42.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com